COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold...
ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics...
– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions,...
Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse eventsFLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE...
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Peter J. Trainer, M.D.,...
A total of 654 adults and children, age six and older, have been enrolled in the INTEGUMENT-1 trialEnrollment continues in...
Management to host conference call and webcast on August 15th at 5:00 pm EDT / 2:00 pm PDTSAN DIEGO, Aug....